Stefan Grass
Keine laufenden Positionen mehr
Vermögen: 63 537 $ am 30.04.2024
Karriereverlauf von Stefan Grass
Ehemalige bekannte Positionen von Stefan Grass
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
CSL Behring AB
 CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Corporate Officer/Principal | - | - |
| BACTIGUARD HOLDING AB | Technik-/Wissenschafts-/F&E-Leiter | 31.10.2019 | - |
Ausbildung von Stefan Grass
| Karolinska Institutet | Doctorate Degree |
Statistik
International
| Schweden | 4 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BACTIGUARD HOLDING AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
CSL Behring AB
CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Health Technology |
- Börse
- Insiders
- Stefan Grass
- Erfahrung
